ALPHA COGNITION INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.7 CAD | +6.06% |
|
-7.89% | +6.06% |
| 05-15 | Alpha Cognition Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 04-04 | Alpha Cognition's Q4 Comprehensive Loss Widens A Bit From Year Earlier Period | MT |
| Sales 2024 * | - | Sales 2025 * | 27M 19.72M 1.56B | Capitalization | 105M 76.87M 6.08B |
|---|---|---|---|---|---|
| Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | - |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 3.9 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.08% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +6.06% | ||
| 1 week | -7.89% | ||
| Current month | -14.63% | ||
| 1 month | -3.45% | ||
| 3 months | -12.50% | ||
| 6 months | +6.06% | ||
| Current year | +6.06% |
1 week
0.65
0.78
1 month
0.650.85
Current year
0.550.99
1 year
0.230.99
3 years
0.192.49
5 years
0.192.49
10 years
0.192.49
| Managers | Title | Age | Since |
|---|---|---|---|
Denis G. Kay
FOU | Founder | - | 31/12/99 |
Michael McFadden
CEO | Chief Executive Officer | 57 | 11/04/21 |
Ken Cawkell
FOU | Founder | 73 | 31/12/19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ken Cawkell
FOU | Founder | 73 | 31/12/19 |
Rajeev Bakshi
BRD | Director/Board Member | 64 | 21/03/21 |
Michael McFadden
CEO | Chief Executive Officer | 57 | 11/04/21 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 28/06/24 | 0.7 | +6.06% | 27,500 |
| 27/06/24 | 0.66 | -4.35% | 17,202 |
| 25/06/24 | 0.69 | -8.00% | 10,350 |
| 24/06/24 | 0.75 | -1.32% | 10,000 |
| 21/06/24 | 0.76 | -2.56% | 12,500 |
Delayed Quote Canadian Securities Exchange, June 28, 2024 at 08:57 pm
More quotes
Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Companyâs pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Companyâs ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimerâs dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS.
Calendar
20/08/2024
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.7
CAD
Average target price
1
CAD
Spread / Average Target
+42.86%
| 1st Jan change | Capi. | |
|---|---|---|
| +6.06% | 76.88M | |
| +19.41% | 45.51B | |
| -8.62% | 38.52B | |
| +38.65% | 38.13B | |
| +26.95% | 30.74B | |
| -13.50% | 26.03B | |
| +10.74% | 25.92B | |
| +44.87% | 14.13B | |
| +34.36% | 12.73B | |
| -7.14% | 11.29B |
- Stock Market
- Equities
- ACOG Stock
